Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. - Wikidata - wikimedia - TriplyDB

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

http://www.wikidata.org/entity/Q39570904

about

Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence HIV and Zika: When will we be able to end these epidemics?Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Active targeted drug delivery for microbes using nano-carriers Efavirenz and the CNS: what we already know and questions that need to be answered Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy What's new for antiretroviral treatment in women with HIV Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025.HIV integrase inhibitors: a new era in the treatment of HIV.Dolutegravir: clinical efficacy and role in HIV therapy.Novel approaches to HIV therapy.Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study Single-Tablet Regimens in HIV Therapy Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.The emerging profile of cross-resistance among the nonnucleoside HIV-1 reverse transcriptase inhibitors.48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection Management of HIV infection in patients with cancer receiving chemotherapy.Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.What if HIV were unable to develop resistance against a new therapeutic agent?Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management.Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.The role of dolutegravir in the management of HIV infection Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.Antiretroviral therapy: when to start

P2860

Q26765043-78BE4125-EAEE-4709-A357-4E5C9FFD2128 Q26778450-7DB51C00-0418-4394-83AC-9C7D30A3F7CA Q26799712-0AB9240B-4910-4803-B562-184B374B9A6A Q26801286-6BD10F80-8211-4C1D-8CC2-C7F46B6BFAB7 Q27927993-498DE220-9A36-48E6-8BBF-4A1F9ECBD3D5 Q28069383-62F93E8C-4BCB-4A86-B687-9BD9CA74A63F Q28079025-CAC63D4F-F99C-4583-AA0D-F39D48D65F64 Q28081266-6DFA63AE-9E4F-4296-879B-1B5BBCC5CECA Q28082463-12428E3D-CABD-4DD5-9992-6B3E13A23947 Q28085028-8113FF77-20EA-4CC8-BECE-D0A61C4C6086 Q28086985-26A197EE-D7FC-4B49-B3AE-83003E52CE1D Q28551873-D63DF6ED-5730-4B88-979F-DD4A0C826F6A Q28552210-DDDDA289-86DE-48A1-AA3B-40ECEB9E5801 Q30391322-6C510FD4-6324-4E94-A387-24397ED93E84 Q30394059-B1292A22-8401-483F-9E36-DAD24B143B87 Q30956943-27D3F9CA-D8FF-43E5-A075-940F9B9B4494 Q33725024-D000F5C4-9590-4751-8372-AC9699AA8B61 Q33777819-9BFEC01F-54EE-45A2-B69B-37EE78273C2A Q33878754-427FE970-071D-45C8-BE32-D93C28A32F75 Q33880221-177A9150-D698-4D32-8EAE-504B1E9F0279 Q33939110-440AAFA5-2BD5-4FDC-AF57-95001BDE7134 Q33963458-748E9D27-909A-4531-A8DA-B04DFCAA7D9B Q34102246-550E5F79-4B3E-402F-9E16-01742C126894 Q34134900-C6088D86-977A-4C33-9DB2-C079C0DC8AB4 Q34202181-B8489A3C-9FF7-44FB-A5F1-B73A399821F4 Q34536677-5CC64F2A-047E-46F3-A1FB-B70FB92B6E71 Q34540677-6FC63646-4B65-4CB2-B287-4CBC076B1FB3 Q34597650-53D10017-998B-48F6-A3FB-37C77DCBEA05 Q34726183-57AAC3B3-501E-44B5-8C5F-51346621F452 Q34736194-0F8376D5-A285-4F67-8B64-7392284138D5 Q34823275-5087261A-F30C-4C94-983E-9792E6C57D7A Q34976284-1BBCB70B-0046-40FA-9014-EE58DD36AF62 Q35008342-1A937A24-C237-4D53-B829-FEA65410EDB3 Q35021555-9DAFF71B-8C93-4511-B1C8-E83B83E3BE5C Q35051393-560EA1F6-0B84-4641-8D54-E58E1CFC76F4 Q35094201-ABC1F380-6884-41E7-B4FC-FBFE7A689683 Q35103606-266282B7-B511-4001-9566-83CF01DF390D Q35121450-96D03C91-6989-4420-85E6-BB462E20FF07 Q35169003-6534A176-0352-423B-AA93-F66A99F13C25 Q35204279-EC3D10AE-A7A9-44C6-A149-07629391D8CA

P2860

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

http://www.wikidata.org/entity/Q39570904

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

@en

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

@nl

type

label

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

@en

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

@nl

prefLabel

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

@en

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

@nl

P1433

Q39570904-C0296878-C81B-465B-BDD5-4E0B6B044E90

P1476

Q39570904-1B060017-6007-4A05-8826-098167EB1744

P2093

Q39570904-03F4BA19-EFC0-4D5E-B018-9E14CD8AD404

Q39570904-045ADE52-AC52-45F5-8ADF-903B6A959D67

Q39570904-27CBCCEC-0409-4BD1-B71C-71ED8D5F51E8

Q39570904-28E526D1-1C2E-4E66-A180-DD670A02E93D

Q39570904-2A900656-420B-4E9C-85AB-47365CE27586

Q39570904-35770CFB-AF78-45DE-869A-17A62EF7E87F

Q39570904-36FD9664-55FA-4F8A-B5DD-791A85DB94AB

Q39570904-5447D56D-DC1E-4821-AFD7-B7DC5E7E5FD9

Q39570904-5647295A-1412-416B-B0E9-19F2ECB3BAE1

Q39570904-6D1B7FCC-38EE-47D3-B6EA-57496DAFBE65

P304

Q39570904-B52FF465-928E-47B3-A186-7540E7DDB15D

P31

Q39570904-EE19DEC9-9036-481C-8BDC-4986F19077DC

P356

Q39570904-C246714E-1899-4D79-A300-58C6DACBFD89

P407

Q39570904-AABB5D69-9FF7-45D7-93D8-7B50B14BC83A

P433

Q39570904-E32F2F0D-D6A6-4BD3-A049-262A2F9DFD74

P478

Q39570904-D8E09C80-2951-4C36-A571-FC1CE0D183B4

P50

Q39570904-1D9CD74C-1A43-4670-8EA3-7183499F1597

Q39570904-5A6EE9BD-15A4-4519-8637-EA39242C4237

P577

Q39570904-A3DF3D96-4FF4-4317-A1EC-764FE4DE7DC2

P698

Q39570904-C405A36A-B530-47F5-BB37-FE45AEEC3E22

P356

P1433

The New England Journal of Medicine

P1476

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

@en

P2093

Andrea Eberhard

http://www.w3.org/2001/XMLSchema#string

Antonio Antela

http://www.w3.org/2001/XMLSchema#string

Brian Wynne

http://www.w3.org/2001/XMLSchema#string

Catherine Granier

http://www.w3.org/2001/XMLSchema#string

Dan Duiculescu

http://www.w3.org/2001/XMLSchema#string

Felix Gutiérrez

http://www.w3.org/2001/XMLSchema#string

Franco Maggiolo

http://www.w3.org/2001/XMLSchema#string

Garrett Nichols

http://www.w3.org/2001/XMLSchema#string

Keith Pappa

http://www.w3.org/2001/XMLSchema#string

Laurent Hocqueloux

http://www.w3.org/2001/XMLSchema#string

P304

1807-1818

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1215541

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

Laurent Hocqueloux

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24195548

http://www.w3.org/2001/XMLSchema#string